NEW
Veletri

Veletri

epoprostenol

Manufacturer:

Janssen

Distributor:

DCH Auriga - Healthcare
Concise Prescribing Info
Contents
Epoprostenol
Indications/Uses
Pulmonary arterial HTN (PAH) (idiopathic or heritable PAH & PAH associated w/ connective tissue diseases) in patients w/ WHO Functional Class III-IV symptoms to improve exercise capacity.
Dosage/Direction for Use
IV Short-term (acute) dose ranging: Initiate at 2 ng/kg/min, increased by increments of 2 ng/kg/min every ≥15 min until max haemodynamic benefit or dose‑limiting pharmacological effects are elicited. Identify lower dose if initial infusion rate is not tolerated. Long-term continuous infusion: Initiate at 4 ng/kg/min less than the max tolerated infusion rate determined during short-term dose-ranging.
Contraindications
Hypersensitivity. CHF arising from severe left ventricular dysfunction. Do not use chronically in patients who develop pulmonary oedema during dose‑ranging.
Special Precautions
Decreasing pH of diluted soln w/ further dilution; restrict peripheral IV use to short duration only, using low conc. Avoid extravasation during administration; consequent risk of tissue damage due to high pH of final infusion soln. Potent pulmonary & systemic vasodilator. Potent inhibitor of platelet aggregation. Reduce dose or discontinue infusion if excessive hypotension occurs. Monitor BP & heart rate during administration. Effects on heart rate may be masked w/ concomitant drugs which affect CV reflexes. Patients w/ CAD. Elevated serum glucose levels. Pulmonary oedema during dose-ranging. Avoid abrupt w/drawal or interruption of infusion (except in life-threatening situations). May affect ability to drive & operate machinery. Discontinue breastfeeding during treatment. Elderly >65 yr. Childn.
Adverse Reactions
Headache; facial flushing; nausea, vomiting, diarrhoea; jaw pain; pain. Sepsis, septicaemia (mostly related to delivery system for Veletri); decreased platelet count, bleeding at various sites (eg, pulmonary, GI, epistaxis, intracranial, post-procedural, retroperitoneal); anxiety, nervousness; tachycardia, bradycardia; hypotension; abdominal colic, sometimes reported as abdominal discomfort; rash; arthralgia; pain at inj site, chest pain.
Drug Interactions
Vasodilator effects may augment or be augmented w/ other vasodilators. Reduced thrombolytic efficacy of tissue plasminogen activator (t-PA). Increased bleeding risk w/ NSAIDs or other drugs affecting platelet aggregation. Elevated conc of digoxin.
ATC Classification
B01AC09 - epoprostenol ; Belongs to the class of platelet aggregation inhibitors excluding heparin. Used in the treatment of thrombosis.
Presentation/Packing
Form
Veletri powd for soln for infusion 1.5 mg
Packing/Price
1's
Form
Veletri powd for soln for infusion 0.5 mg
Packing/Price
1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in